VTRS:NSD-Viatris Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 12.08

Change

0.00 (0.00)%

Market Cap

USD 14.04B

Volume

6.72M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-31 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+0.97 (+0.80%)

USD 12.37B
ITCI Intracellular Th

+0.16 (+0.21%)

USD 7.67B
LNTH Lantheus Holdings Inc

+1.52 (+1.46%)

USD 7.38B
ALKS Alkermes Plc

+1.10 (+4.14%)

USD 4.55B
ALVO Alvotech

+0.01 (+0.09%)

USD 3.26B
HCM HUTCHMED DRC

+0.61 (+3.66%)

USD 2.98B
AMPH Amphastar P

+1.57 (+3.37%)

USD 2.28B
SUPN Supernus Pharmaceuticals Inc

+0.21 (+0.68%)

USD 1.93B
KNSA Kiniksa Pharmaceuticals Ltd

+0.77 (+3.14%)

USD 1.78B
INDV Indivior PLC Ordinary Shares

+0.28 (+2.91%)

USD 1.57B

ETFs Containing VTRS

FHH:CA First Trust AlphaDEX US H.. 2.41 % 0.77 %

N/A

CAD 0.01B
FHH-F:CA First Trust AlphaDEX U.S... 2.41 % 0.00 %

N/A

CAD 0.01B
FXH First Trust Health Care A.. 2.29 % 0.63 %

+0.86 (+0.78%)

USD 1.26B
RSPH Invesco S&P 500® Equal.. 1.77 % 0.00 %

+0.25 (+0.78%)

USD 1.02B
CVY Invesco Zacks Multi-Asset.. 1.12 % 0.65 %

+0.28 (+0.78%)

USD 0.12B
DON WisdomTree U.S. MidCap Di.. 0.00 % 0.38 %

+0.84 (+0.78%)

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

+0.35 (+0.78%)

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

+0.38 (+0.78%)

N/A
DUSA 0.00 % 0.63 %

N/A

N/A
RPV Invesco S&P 500® Pure Va.. 0.00 % 0.35 %

+0.85 (+0.78%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+0.81 (+0.78%)

N/A
XXM:CA 0.00 % 0.68 %

N/A

N/A
UMI:CA CI U.S. MidCap Dividend I.. 0.00 % 0.41 %

N/A

CAD 0.02B
XMMD:LSE Xtrackers - MSCI Emerging.. 0.00 % 0.00 %

+0.54 (+0.78%)

N/A
UMI-B:CA CI WisdomTree U.S. MidCap.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.54% 43% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.54% 43% F 62% D
Trailing 12 Months  
Capital Gain 11.96% 35% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.96% 35% F 59% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.03% N/A N/A 29% F
Dividend Return -4.56% N/A N/A 31% F
Total Return 2.47% N/A N/A 55% F
Risk Return Profile  
Volatility (Standard Deviation) 15.44% N/A N/A 82% B
Risk Adjusted Return -29.51% N/A N/A 25% F
Market Capitalization 14.04B 99% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector